ELZONRIS
Total Payments
$4.5M
Transactions
3,624
Doctors
2,140
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 714 | 490 |
| 2023 | $69,576 | 274 | 209 |
| 2022 | $2.3M | 567 | 392 |
| 2021 | $214,020 | 533 | 387 |
| 2020 | $276,189 | 617 | 362 |
| 2019 | $274,038 | 919 | 601 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 114 | 65.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $698,384 | 230 | 15.6% |
| Consulting Fee | $509,832 | 99 | 11.4% |
| Honoraria | $124,845 | 53 | 2.8% |
| Food and Beverage | $119,278 | 2,587 | 2.7% |
| Travel and Lodging | $106,629 | 386 | 2.4% |
| Education | $2,628 | 155 | 0.1% |
Payments by Type
Research
$2.9M
114 transactions
General
$1.6M
3,510 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | Stemline Therapeutics Inc. | $720,762 | 0 |
| STML-401-0114 | Stemline Therapeutics Inc. | $681,603 | 0 |
| Dana Farber Cancer Institute | Stemline Therapeutics Inc. | $539,178 | 0 |
| STML-401-0314 | Stemline Therapeutics Inc. | $345,360 | 0 |
| Tagraxofusp (SL-401) in Patients With CMML or MF | Stemline Therapeutics Inc. | $246,407 | 0 |
| STML-IST-PEM | Stemline Therapeutics Inc. | $149,069 | 0 |
| STML-IST-SHOR | Stemline Therapeutics Inc. | $120,000 | 0 |
| STML-IST-GMB | Stemline Therapeutics Inc. | $60,870 | 0 |
| STML-IST-BASH | Stemline Therapeutics Inc. | $45,548 | 0 |
| STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | Stemline Therapeutics Inc. | $5,436 | 11 |
Top Doctors Receiving Payments for ELZONRIS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Thomas Lee | — | Peoria, AZ | $2.9M | 116 |
| , M.D | Anatomic Pathology & Clinical Pathology | Los Angeles, CA | $231,175 | 117 |
| , M.D | Specialist | Bethesda, MD | $141,250 | 1 |
| , MD | Dermatopathology | Charlottesville, VA | $92,095 | 69 |
| , M.D | Medical Oncology | Durham, NC | $75,963 | 66 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $71,820 | 49 |
| , M.D | Hematology | Hackensack, NJ | $64,179 | 43 |
| , MD | Anatomic Pathology | Los Angeles, CA | $63,942 | 52 |
| , MD | Dermatology | Fairport, NY | $62,502 | 63 |
| , M.D | Internal Medicine | Boston, MA | $50,300 | 14 |
| , M.D | Dermatology | Los Angeles, CA | $45,294 | 39 |
| , MD | Medical Oncology | Bellaire, TX | $36,000 | 6 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $32,179 | 23 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $27,749 | 18 |
| , MD | Hematology | Buffalo, NY | $22,620 | 16 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $22,439 | 14 |
| , M.D | Hematology & Oncology | Chagrin Falls, OH | $21,458 | 13 |
| , MD | Internal Medicine | Chicago, IL | $20,541 | 18 |
| , M.D | Dermatology | Rochester, MN | $17,577 | 18 |
| , MD | Internal Medicine | San Francisco, CA | $15,805 | 13 |
| , MD | Hematology & Oncology | San Diego, CA | $15,455 | 13 |
| Miki Haraguni | Family | Thousand Oaks, CA | $15,446 | 33 |
| , ANP-BC | Nurse Practitioner | Chicago, IL | $14,351 | 32 |
| , M.D | Anatomic Pathology & Clinical Pathology | Lakeland, FL | $11,495 | 10 |
| Rebecca Nelson | Family | Tampa, FL | $10,045 | 8 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 2,140
- Transactions 3,624
About ELZONRIS
ELZONRIS is a drug associated with $4.5M in payments to 2,140 healthcare providers, recorded across 3,624 transactions in the CMS Open Payments database. The primary manufacturer is Stemline Therapeutics Inc..
Payment data is available from 2019 to 2024. In 2024, $1.4M was paid across 714 transactions to 490 doctors.
The most common payment nature for ELZONRIS is "Unspecified" ($2.9M, 65.1% of total).
ELZONRIS is associated with 10 research studies, including "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme" ($720,762).